Review Article Open Access

The Availability and Absorption Characteristics of a Healthy Dose of Recombinant Human Growth Hormone (GH) Delivered Subcutaneously in Adults with GH Deficiency

Abstract

Goals: In females with GH Deficiency (GHD), to examine the absorption profile and calculate the bioavailability of three doses of recombinant human Growth Hormone (rhGH) less than 2 IU. Comparing the mean 24-hour GH concentrations following s.c. rhGH injection to the physiological mean 24-hour GH concentration of healthy females of similar age, height, and BMI was the study's second goal. Techniques The study included 14 female patients with substituted GHD and 14 healthy females with similar BMI, height, and age. Following an intraperitoneal injection of rhGH at dosages of 0.6, 1.2, or 1.8 IU, all GHD patients had a 24- hour GH sample. Furthermore, these individuals received an intravenous injection of rhGH (1 IU) followed by a 4-hour GH sampling. When well For a 24- hour period, patients' blood was collected every 10 minutes to ascertain their physiological GH profile. Outcomes: A mean and maximum GH concentration of 0.95 ± 0.04 mU l−1 and 2.62 ± 0.09 mU l−1 were obtained with a single 0.6 IU s.c. dosage. The mean and maximum GH levels doubled (or tripled) in response to a doubling (or tripling) of the rhGH dose. The average time to attain the highest concentration of GH was 261 ± 27 minutes. After receiving a single-dose 1.2 IU of growth hormone, the mean concentration of GH in healthy females was found to be similar. The S.C. administered dose's mean availability was 63% ± 4%. Conclusion: When 1.2 IU was administered, the mean GH concentration in healthy females was found to be similar to the mean physiological GH concentration similar BMI, age, and height.

Hari Prasad Sonwani1*, Aakanksha Sinha2

To read the full article Download Full Article